image credit- freepik
Menarini Asia-Pacific has announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and distribute Cosela® (trilaciclib) across its Asia-Pacific markets.
Chemotherapy-induced myelosuppression (CIM) is a potentially debilitating side effect that damages bone marrow, significantly impacting its hematopoietic function (or its ability to produce healthy blood cells).
For patients with extensive-stage small cell lung cancer (ES-SCLC), chemotherapy remains a cornerstone of treatment, yet it is a major dose limiting complication that can disrupt treatment and compromise outcomes.
Cosela® is a first-in-class prophylactic therapy FDA approved to help protect bone marrow from CIM, addressing a significant unmet need in oncology supportive care for these patients.
Under the agreement, Menarini Asia-Pacific will manage all aspects of registration, reimbursement, commercialisation and distribution of Cosela® in Australia, Hong Kong/Macau, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.
Cosela® is currently marketed in the United States and China and is under registration in Europe. Subject to regulatory approvals, the first Asia-Pacific launch is anticipated in Hong Kong in 2028, followed by other markets thereafter.
